Complex immunotherapy-mediated response patterns depicted on serial F-FDG PET imaging of Hodgkin lymphoma patient undergoing pembrolizumab therapy.

Over the past decade, the role of F-Fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing treatment response for lymphoma patients undergoing immunotherapy has been extensively investigated. The advent of immunotherapy has challenged the utility of the established Lugano criteria, prompting the development of novel immunotherapy-specific response criteria now employed in clinical practice. Following F-FDG PET/CT evaluation after up to eight immunotherapy cycles, patients are typically transitioned to conventional imaging modalities if immunotherapy continuation is warranted.